SCHEMBL7081591

SCHEMBL7081591

CCN(CC)CCNC(=O)c1ccc(C)nc1Nc1ccc2cn[nH]c2c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SYK P43405 2/20 0.43
PDGFRB P09619 1/20 0.43
PDGFRA P16234 1/20 0.43
KDR P35968 1/20 0.42
HPGD P15428 2/20 0.41
IGF1R P08069 3/20 0.41
RPS6KB1 P23443 2/20 0.41
SMN1; SMN2 Q16637 3/20 0.41
KDM4E B2RXH2 3/20 0.41
RECQL P46063 1/20 0.41
ALDH1A1 P00352 1/20 0.41
NPC1 O15118 2/20 0.41
RAB9A P51151 2/20 0.41
LMNA P02545 1/20 0.41
POLR1A O95602 1/20 0.40
CYP1A2 P05177 1/20 0.40
KCNH2 Q12809 1/20 0.40
MCHR1 Q99705 1/20 0.40
HDAC1 Q13547 1/20 0.40
HDAC6 Q9UBN7 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7083122 0.90 RPS6KB1 (0.49) SYKPDGFRBPDGFRAKDRHPGD
SCHEMBL7081409 0.87 SYK (0.46) SYKPDGFRBPDGFRAKDRHPGD
SCHEMBL7081452 0.82 SYK (0.50) SYKPDGFRBPDGFRAKDRHPGD
SCHEMBL7078467 0.81 PDGFRB (0.56) SYKPDGFRBPDGFRAIGF1RALDH1A1
SCHEMBL7079281 0.81 ALDH1A1 (0.51) HPGDSMN1; SMN2KDM4EALDH1A1NPC1
SCHEMBL7081454 0.79 SYK (0.53) SYKKDRHPGDIGF1RRPS6KB1
SCHEMBL7077905 0.79 PDGFRB (0.67) PDGFRBPDGFRAKDRSMN1; SMN2KDM4E
SCHEMBL7082077 0.79 SYK (0.52) SYKPDGFRBPDGFRAKDRHPGD
SCHEMBL7083647 0.79 SYK (0.48) SYKPDGFRBPDGFRAKDRHPGD
SCHEMBL7077410 0.79 SYK (0.52) SYKKDRHPGDSMN1; SMN2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6608058-B2 Therapeutic composition for hepatitis B, hepatitis C, or acquired immune deficiency syndrome DONG WHA PHARM. IND. CO., LTD. (KR) 2003-08-19 US claimed
US-20030092709-A1 6-Methylnicotinamide derivatives as antiviral agents DONG WHA PHARM. CO., LTD. (KR) 2003-05-15 US claimed
US-6608058-B2 Therapeutic composition for hepatitis B, hepatitis C, or acquired immune deficiency syndrome DONG WHA PHARM. IND. CO., LTD. (KR) 2003-08-19 US disclosed
US-20030092709-A1 6-Methylnicotinamide derivatives as antiviral agents DONG WHA PHARM. CO., LTD. (KR) 2003-05-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030092709-A1 6-Methylnicotinamide derivatives as antiviral agents TPMT, HAVCR2, NNMT SYK 4369/4885PDGFRB 3908/4885PDGFRA 3543/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.